Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01985360 · ClinicalTrials.gov registry record · Phase 4
ISCHEMIA-Chronic Kidney Disease Trial
A Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 777
- Enrollment target
- 1
- Study location
NCT01985360: Completed Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease, sponsored by NYU Langone Health.
NCT01985360 is a Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease that has completed, run by NYU Langone Health. The registered enrollment target is 777 participants, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01985360, a Phase 4 study of Cardiovascular Diseases and Coronary Artery Disease, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 777 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate inducible ischemia and advanced chronic kidney disease (CKD; estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m² or on dialysis). This is a multicenter randomized controlled trial of 777 randomized participants with advanced CKD. Participants were assigned at random to a routine invasive strategy (INV) with cardiac catheterization (cath) followed by revascularization (if suitable) plus optimal medical therapy (OMT) or to a conservative strategy (CON) of OMT, with cath and revascularization reserved for those who fail OMT. The trial is designed to run seamlessly in parallel to the main ISCHEMIA trial as a companion trial. SPECIFIC AIMS A. Primary Aim. The primary aim of the ISCHEMIA-CKD trial is to determine whether an invasive strategy of cardiac cath followed by optimal revascularization, in addition to OMT, will reduce the primary composite endpoint of death or nonfatal myocardial infarction in participants with SIHD and advanced CKD over an average follow-up of approximately 2.8 years compared with an initial conservative strategy of OMT alone with catheterization reserved for those who fail OMT. The primary endpoint is time to centrally adjudicated death or nonfatal myocardial infarction (MI). B. Secondary Aims. Major: To compare the incident of the composite of death, nonfatal MI, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure, and angina symptoms and quality of life, as assessed by the Seattle Angina Questionnaire, between the INV and CON strategies. Other secondary aims include: comparing the incidence of the composite of death, nonfatal MI, hospitalization for unstable angina, hospitalization for heart failure, resuscitated cardiac arrest, or stroke; composite of death, nonfatal MI, or stroke; composite endpoints incorporating cardiovascular death; c
Conditions Studied
Interventions
- PROCEDURE Cardiac Catheterization
- BEHAVIORAL Lifestyle
- DRUG Medication
- PROCEDURE Coronary Artery Bypass Graft Surgery
- PROCEDURE Percutaneous Coronary Intervention
Study Locations (1)
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 777 participants |
| Start Date | 2014-01 |
| Est. Completion | 2020-07 |
| Phase | Phase 4 |
What the finished NCT01985360 record still lists
NCT01985360 is an interventional study that assigns participants to a tested intervention. The registered 777 participants enrollment target is mid-sized for trials with a published cap, below the 26,972-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower).
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 5 interventions - of which Cardiac Catheterization is the first listed.
NCT01985360 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01985360 about?
NCT01985360 is a clinical study titled "ISCHEMIA-Chronic Kidney Disease Trial". The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate inducible ischemia and advanced chronic kidney disease (CKD; estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m² or on dialysis)....
What is the current status of trial NCT01985360?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 777 participants. The study started on 2014-01. Estimated completion is 2020-07.
What conditions does trial NCT01985360 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia, Kidney Disease.
What interventions are being tested in trial NCT01985360?
The interventions under investigation include: Cardiac Catheterization (PROCEDURE), Lifestyle (BEHAVIORAL), Medication (DRUG), Coronary Artery Bypass Graft Surgery (PROCEDURE), Percutaneous Coronary Intervention (PROCEDURE).
Who is sponsoring clinical trial NCT01985360?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01985360 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01985360's enrollment target sits among peer trials
777 72nd of 300 higher than 229 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05642611 · 777 participants · Phase 3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
- NCT06841679 · 778 participants · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06145763 · 776 participants · NA
A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial
- NCT03460769 · 775 participants
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia